This Week in NEJM

Premium

In NEJM this week, a team of European researchers reports its assessment of JAK inhibitor ruxolitinib versus the best available therapy for the treatment of myelofibrosis, a form of chronic leukemia. The team assigned 219 myelofibrosis patients to receive either ruxolitinib or the best available therapy, and found that 28 percent of the patients in the ruxolitinib group had at least a 35 percent reduction in spleen volume, compared to 0 percent in the best available treatment group.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.